North Point Portfolio Managers Corp OH Sells 1,372 Shares of Danaher Co. (NYSE:DHR)

North Point Portfolio Managers Corp OH lowered its position in Danaher Co. (NYSE:DHR) by 2.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 67,667 shares of the conglomerate’s stock after selling 1,372 shares during the quarter. Danaher accounts for about 2.7% of North Point Portfolio Managers Corp OH’s holdings, making the stock its 13th largest position. North Point Portfolio Managers Corp OH’s holdings in Danaher were worth $15,533,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Decker Retirement Planning Inc. bought a new position in Danaher during the fourth quarter worth about $31,000. Teachers Insurance & Annuity Association of America bought a new position in shares of Danaher during the third quarter valued at $39,000. MidAtlantic Capital Management Inc. bought a new stake in shares of Danaher in the 3rd quarter worth about $40,000. FSA Wealth Management LLC acquired a new stake in shares of Danaher during the 3rd quarter worth about $50,000. Finally, Darwin Wealth Management LLC bought a new position in Danaher during the 3rd quarter valued at about $55,000. 79.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on DHR shares. UBS Group decreased their price objective on shares of Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Barclays dropped their price target on Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. Guggenheim began coverage on Danaher in a research note on Thursday, December 19th. They issued a “buy” rating and a $275.00 target price for the company. Finally, Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target on the stock in a research report on Thursday, October 31st. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, Danaher has an average rating of “Moderate Buy” and a consensus target price of $285.55.

Danaher Price Performance

Shares of DHR opened at $245.95 on Monday. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The stock has a market cap of $177.65 billion, a P/E ratio of 46.94, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. The stock’s 50-day moving average price is $235.33 and its two-hundred day moving average price is $253.62. Danaher Co. has a 1 year low of $225.42 and a 1 year high of $281.70.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be paid a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.44%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s payout ratio is presently 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.